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Original Article
Abstract
Osteoporosis is rapidly turning into a global epidemic, leading to high rates of morbidity and mortality due to the resulting complications such as osteoporotic 
fractures in older people. Therefore, this review investigated the findings of clinical trials regarding the effects of medicinal herbs on osteoporosis. To this end, 
several keywords were used to search for relevant articles indexed in the Institute for Scientific Information and PubMed, including “Osteoporosis” or “Bone 
loss” AND “medicinal plant” or “phyto*” or “herb*”. Finally, 43 articles were included in the review. There are several mechanisms for anti-osteoporosis 
effects. Estrogen-like effects, especially soy phytoestrogenic compounds and other herbal compounds and formulations, can enhance bone formation markers, 
as well as antioxidant and anti-inflammatory capacity, while decreasing bone resorption biomarkers. Therefore, they can be used as complementary medicine 
for osteoporosis, especially in postmenopausal older women. However, for more reliable evidence, further studies are still needed because most studies have 
addressed soy, and the number of randomized controlled trials conducted on other herbal drugs is small. The plants possess the androgen-like properties that 
play an important role in the promotion of bone health. In addition, herbal treatments are supportive and slow-acting and thus such treatments are suggested 
for prevention and maintenance purposes rather than fast-acting treatments. 
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Introduction 
Osteoporosis is considered a serious growing health issue 
that causes many osteoporotic fractures globally each year 
due to impaired bone quality (1). In addition, osteoporosis 
is responsible for impaired stem cell differentiation and 
impaired bone microarchitecture/mineralization, especially 
in older women (2). Although this disease can be clinically 
silent and the people do not usually undergo screening 
and prevention measures for it, the cost of osteoporotic 
fractures imposes a heavy burden on the healthcare system 
(3,4). The disease also substantially decreases the quality of 
life in patients and elder women (5). Further, osteoporosis 
is a multifactorial disorder and its risk factors include 
age over 65 years, postmenopausal estrogen loss or age 
associated with the deterioration of the microarchitecture, 
along with the family history of fracture, smoking, obesity, 
and low body mass index. The disease has also secondary 
risk factors that encompass underlying disorders and the 
use of certain drugs (2). Therefore, several therapeutic 
strategies are available to fight the disease. Although 
there are several anti-osteoporotic drugs and treatments 
of choice for improving bone mineral density (BMD), 
numerous needs remain unmet and several side effects 
and treatment failures are also reported due to therapeutic 
methods (6,7). Nowadays, the use of medicinal plants is 
growing for the treatment of various diseases. Fewer side 
effects, cost-effectiveness, and convenient access have 
positively contributed to the popularity of medicinal plant-
based treatments (8). Although medicinal plants and their 
derivatives can effectively maintain the bone metabolism 
in a balanced state and increase lumbar spine BMD, herbal 
treatments have not come up with convincing outcomes 
regarding the treatment or prevention of osteoporosis 
(9,10). 
Many articles have acknowledged the therapeutic value 
of medicinal plants although these theories do not rely 
on reliable data from clinical trials. Therefore, the present 
review article evaluated the effects of medicinal plants on 
osteoporosis according to the results of clinical trials.
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Materials and Methods
To conduct this review article, keywords such as 
“Osteoporosis” or “Bone loss” AND “medicinal plant” 
or “phyto*” or “herb*” were utilized to search for 
relevant articles indexed in the Institute for Scientific 
Information and PubMed using the EndNote software. 
A standard form was also prepared, including items such 
as the author, the title or purpose of the study, medicinal 
plant or formulation(s) or constitute(s) names, the type 
of intervention, the dosage, the duration, outcome, 
publishing journal, and the number of co-authors. Then, 
the full texts of the articles that fulfilled the purpose of 
the review were included in the analysis after achieving 
the agreement of the co-authors, followed by recording 
the above-mentioned information in the form. Next, 
clinical trials conducted on osteoporosis were considered 
as the inclusion criteria. Moreover, the articles that had a 
positive effect on osteoporosis were included in the review. 
However, those articles reporting studies with non-positive 
effects, review articles, articles with inaccessible full texts, 
non-English language articles, and studies irrelevant to the 
main aim of the review were excluded after obtaining the 
agreement of all authors. Overall, 43 studies were included 
in the final analysis (Figure 1). 
Results
The use of medicinal plant-based products and derivatives 
is considered as a convenient and cost-effective method 
for improving bone health. They even can be used as a 
food or dietary supplement to prevent postmenopausal 
osteoporosis. The interventions were reported to exert 
inflammatory and metabolic impacts, to decrease turnover 
markers and increase calcium conservation (11,12). A 
Figure 1. Flowchart of the Article Selection
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Table 1. Medicinal plants, formulations, and compounds with preventive and therapeutic effects against osteoporosis
Medicinal Plants
Herbal Scientific Name Dose/Duration
Type of 
Administration
Outcome References
Acanthopanax senticosus 3 g per day for 6 months Powder extract
Have beneficial effects on bone 
remodeling in postmenopausal women
Hwang et al (13)
Trifolium pratense
150 mL red clover extract containing 
37.1mg isoflavones for 12 weeks
Extract 
supplementation
Improved bone health in menopausal 
women based on BMD and T-score
Thorup et al (14)
Medicinal Plant Formula
Herbal Compound Name Dose/Duration
Type of 
Administration
Outcome References
Kidney-tonifying prescription
25 mL was taken twice daily for 8 
months
Dilution
Significantly increased the level of 
estradiol and BMD
Zhao et al (15)
Yang Huo San Zi Tang
Two Gaierqi D tablets as a daily dose for 
6 months
Tablet
Increased bone growth protein, BMD, 
and estradiol after 3 and 6 months
Qiu et al (16)
Yigu capsule 4 capsules each time, 3 times a day Capsule
Increased the BMD, alleviated the rate 
of ostealgia and inhibited the absorption 
of bone while elevating the sex hormone 
level
Zhang et al (17)
Bo-gu Ling
6 capsules (380 mg/capsule) once daily 
for 12 months
Capsule
Improved BMD on the women who 
experienced over 10 years of menopause
Leung et al (18)
Yang tonic formula 18 g twice daily for 6 months Dilution
Improved bone mass without adverse 
effects
Yang et al (19)
Xian Ling GuBao 3 and 6 g/day for 1 year Capsule
Significantly increased BMD at 6 months 
in a safe manner
Zhu et al (20)
Qing’e formula
For every 100 g of the powder 50–70 
g of refining honey was added for 
producing the Qing’e pill. QEF was 
administered three times daily with warm 
water plus Caltrate and 600 mg daily in 
QEF+calcium group for 6 months
Supplementation
Decreased the levels of C-telopeptide 
(β-CTX), N-MID, and type I procollagen-
N-propeptide (P1NP) and modulated 
bone metabolism in patients with 
postmenopausal osteoporosis
Yang et al (21)
QiangGuYin 20 g/day for 12 months
Concentrated
decoction
Increased BMD while it decreased 
β-CTX and P1NP
Shi et al. (22)
Linum usitatissimum + sesame 
indicum + Cicer canaries and 
palm pollen grain
40 gr mixture seeds for 3 months
Powder 
supplementation
Improved the BMD of postmenopausal 
women who suffered from bone fragility
Alshafei et al (23)
Xianling Gubao 3 tablets twice a day for 12 weeks Capsule
Improved BMD and the level of blood 
calcium while it decreased the level 
of blood phosphorus and alkaline 
phosphatase (AKP)
Guo et al (24)
Fufang Xian Ling GuBao Twice daily for 6 months Capsule
Prevented the corticosteroid-associated 
osteonecrosis of the femoral head in 
patients with immune-inflammatory
Li et al (25)
Ziyin Jianghuo Ningxin
25 mg was taken each time, twice per 
day for 3 months
Capsule
Improved BMD of postmenopausal 
women
Lin et al (26)
Morus alba and Polygonum 
odoratum
2 doses of 50 and 1500 mg/d for 8 weeks Extract
Improved serum AKP, osteocalcin, and 
total phenolic compound content but 
decreased β-CTX level
Wattanathorn et 
al (27)
Cheong-A-Won 9 g 3 times a day for 24 weeks Capsule Significant increase in BMD and t-score Yun et al. (28)
Bushen Yijing Fang
0.55 g/capsule, 3 capsules/time, 3 times/
day for 36 months
Capsule
Improved BMD and t-score in women 
with osteopenia
Zheng et al (29)
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Medicinal Plant Constitutes
Herbal Derivative Name Dose/Duration
Type of 
Administration
Outcome References
Soy isoflavone
12 consecutive weeks with 60 mg/d of 
isoflavones
Supplementation
Increased serum levels of phytoestrogens 
while it diminished several key clinical 
risk factors for
osteoporosis in normal postmenopausal 
women
Scheiber et al (30)
Soy isoflavone 2 meals twice a week with two meals Supplementation
Stimulates bone osteoblastic activity and 
augmented in osteocalcin concentrations
Chiechi et al (31)
Soy isoflavone
Mid-dose (40 mg) and high-dose (80 mg) 
for 12 months
Capsule
Increased the maintenance of the 
hip bone mineral content in later 
menopause or those with lower body 
weight or calcium intake
Chen et al (32)
Soy isoflavone 126 mg isoflavones for 6 months
Extract
powder
Reduced bone loss possibly via the 
inhibition of bone resorption in non-
obese postmenopausal women
Ye et al (33)
Soy isoflavone
75 mg of isoflavone conjugates/day for 
1 year
Supplementation
Prevented the isoflavones on bone 
loss and fat accumulation in early 
postmenopausal women
Wu et al (34)
Soy isoflavone 80 or 120 mg/d for 3 years Tablet
Increased volumetric BMD in 
postmenopausal women
Shedd et al (35)
Soy isoflavone 70 mg/d for 12 weeks Supplementation
Increased bone formation markers 
such as serum bone-specific alkaline 
phosphatase and osteocalcin
Lee et al (36)
Soy isoflavone
20 mg genistein and daidzein, two 
capsules, meaning 40 mg p.o. daily for 
1 year
Capsule
Affected BMD, bone resorption, and 
bone metabolism in postmenopausal 
women
Tit et al (37)
Soy isoflavone and protein
15 g soy protein with 66 mg isoflavone 
or 15 g soy protein alone, daily for 6 
months
Supplementation Reduced β-CTX andP1NP
Sathyapalan et 
al (38)
Soy phytoestrogens 200 mg daily for 2 years Tablet
Prevented bone loss and menopausal 
symptoms in menopause women
Levis et al (39)
Soy phytoestrogens 35 g soy protein per day for 12 weeks Supplementation
Caused delay bone resorption and 
prevented osteoporosis
Roudsari et al (40)
Soy protein with isoflavones
99 mg of isoflavones in 25.6 g of soy 
protein for 1 year
Supplementation
Increased BMD in postmenopausal 
women
Kok et al (41)
Phytoestrogen genistein 54 mg/d of genistein daily for 24 months Supplementation Increased BMD in genistein prescription Marini et al (42)
Phytoestrogen genistein 54 mg/d of genistein daily for 12 months Tablet
Positive effect on bone and reduction of
cytogenetic biomarkers
Atteritano et al 
(43)
Phytoestrogen genistein
54 mg of genistein aglycone daily for 3 
years
Tablet
Had positive effects on bone formation 
and osteopenia in postmenopausal 
women
Marini et al (44)
Phytoestrogen genistein 54 mg/d daily for 2 years Tablet
Improved the phalanges ultrasound 
parameters and prevented bone loss in 
osteopenic postmenopausal women
Atteritano et al 
(45)
Phytoestrogen genistein 10 capsules/tablets per intervention Supplementation
Suppressed net bone resorption in 
postmenopausal women
Weaver et al (46)
Phytoestrogen genistein 30 mg/d for 6 months Capsule
Prevented osteoporosis and reduced 
fracture risk in postmenopausal women
Lappe et al (47)
Phytoestrogen genistein
2 doses of a genistein-rich soy 
supplement and 3 doses of mixed 
isoflavones in various proportions for 
50 days
Supplementation
Soy isoflavones were effective on bone-
preserving agents in postmenopausal 
women and mixed isoflavones in their 
natural ratios were more effective than 
enriched genistein
Pawlowski et al 
(48)
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total of 52 articles were included in the final analysis after 
studying the articles by two of the co-authors and according 
to the inclusion and exclusion criteria.
Medicinal plants and their compounds can be effective 
against osteoporosis via various mechanisms of action 
(Table 1).
Discussion
In this study, medicinal plants were found to prevent or 
reduce the symptoms of osteoporosis through several 
mechanisms. Conversely, however, some studies showed 
that these natural medicines may not have an impact on 
this disease. For example, in the study of Brink et al., 
supplementation with 110 mg/d of soy isoflavone aglycone 
for one year in postmenopausal women failed to prevent 
postmenopausal bone loss or affect bone turnover (54). 
Similarly, another study indicated that 200 mg of soy 
isoflavones daily for 2 years did not prevent bone loss 
in menopausal women (55). Consistently, some studies 
have reported that treatment with isoflavones (aglycone 
equivalents), Trifolium pratense extract, and semelil 
(Angipars W) could not prevent a decline in BMD and 
had no significant effect on bone biomarkers and thus 
bone health (56-59). According to previous studies and 
the present one, it seems that differences in the study 
populations and the lack of controlling for confounding 
factors such as soy or phytoestrogens consumption in the 
control group may have led to these inconsistencies. The 
concomitant treatments, the duration of the studies, and 
the administration route of the herbal compounds may 
have also contributed to these differences.
Based on the findings of this review study, there are 
several mechanisms for the effect of medicinal plants 
on osteoporosis. Osteoporosis is characterized by 
skeletal degeneration with a reduction in BMD and 
the deterioration of the microarchitecture of the bone 
tissue, which leads to a fracture (60). This disease is 
more prevalent in postmenopausal women than older 
men because these women are more likely to develop 
osteoporosis compared to men due to massive declines 
in estrogen levels during menopause, which can lead to 
an increase in the bone-resorption activity and a decline 
in bone formation (61,62). Estrogenic compounds like 
phytoestrogens affect bone via promoting the production 
of calcitonin, lowering the sensitivity of bone mass to 
parathyroid hormone, reducing the calcium excretion from 
the kidney, and accelerating intestinal calcium resorption. 
Further, estrogen can directly influence the bone, which, 
in turn, can inhibit bone resorption and increase bone 
density (63). Another mechanism is the anti-inflammatory 
and antioxidant effects of medicinal plants. Furthermore, 
inflammation cytokines exert substantial impacts on 
bone loss and osteoporosis (2). Phytoestrogens are able to 
suppress the production of proinflammatory cytokines like 
tumor necrosis factor-alpha (TNF-α), IL-1, IL-6, and IL-7 
as well. This is why these proinflammatory cytokines are 
elevated in postmenopausal women (64). In addition, the 
antioxidant capacity of herbal drugs can serve to scavenge 
free radicals, leading to the inhibition of cyclooxygenase-2 
(COX-2) and TNF-α production and expression. This 
results in a decrease in the receptor activator of NF-κβ 
ligand (RANKL) expression (RANKL-stimulated RAW 
264.7 cells also in bone marrow-derived macrophages), 
leading to a decline in the osteoclast activity, which, finally, 
reduces bone loss (64-66).
Moreover, herbal drugs can promote bone formation 
markers such as AKP, serum 25-hydroxyvitamin D, bone 
Gla protein, and osteocalcin but decrease bone resorption 
markers like serum collagen type 1and β-CTX. Figure 2 
summarizes the most important mechanisms of medicinal 
plants and their derivatives reported in clinical trials.
Although plant compounds are considered natural, 
Genistein Aglycone 54 mg/d for 2 years Tablet
It was useful not only in postmenopausal 
osteopenia but also in women with 
osteoporosis
Arcoraci et al (49)
Tofupill/Femarelle (DT56a)
644 mg/d DT56a (study group) or 344 
mg/d DT56a for 12 months
Supplementation
Increased BMD without unwanted 
estrogenic effect
Yoles et al (50)
Epimedium-Derived 
Phytoestrogen Flavonoids
A daily dose of 60 mg Icariin, 15 mg 
Daidzein, and 3 mg genistein for 24 
months
Capsule
Prevented bone loss without resulting in 
endometrium hyperplasia effect
Zhang et al (51)
Hop rho iso-alpha acids and 
berberine
200 mg hop rho iso-alpha acids 100 
mg berberine sulfate trihydrate, 500 IU 
vitamin D3, and 500 μg vitamin K1 twice 
daily for 14 weeks
Tablet
Decreased serum osteocalcin and 
concentrations, increased serum 
25-hydroxyvitamin D concentrations, 
and increased serum insulin-like growth 
factor I concentrations
Lamb et al (52)
β-cryptoxanthin plus 
phytosterols
b-Cx (0.75 mg/d) and PS (1.5 g/d) for 4 
weeks
Supplementation
Combination therapy decreased 
bone turnover markers and the risk of 
osteoporosis
Granado et al (53)
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they can lead to certain complications under certain 
circumstances such as the type of plant, dosage, and 
the duration of use. A meta-analysis demonstrated that 
the long-term consumption of phytoestrogens did not 
significantly increase the side effects such as endometrial 
hyperplasia, vaginal bleeding, endometrial cancer, and 
breast cancer, but elevated the rates of gastrointestinal side 
effects (67). In this review, the side effects had also been 
included and reported in some studies. Such side effects 
were reported following the consumption of higher doses 
of plant compounds, and certain side effects were widely 
developed after the consumption of phytochemicals. For 
example, some studies reported that high doses of genistein 
can cause gastrointestinal complications (42,43,49).
The main limitation in most clinical trials was the lack 
of making any comparisons between different doses of 
herbal derivatives and different populations as well as the 
lack of control for the confounding factors. According 
to our review, previous randomized controlled trials 
addressed very few herbal plants in order to evaluate their 
pharmacological effects on humans’ bone health, most of 
which were conducted on soy phytochemicals. Therefore, 
more rigorous research should be done on these plants to 
evaluate their anti-osteoporotic properties.
Conclusion
Medicinal plants and their derivatives can be used to enhance 
bone formation markers, along with antioxidant and 
anti-inflammatory capacity, but decrease bone resorption 
biomarkers. Thus, they can be utilized as complementary 
medicine for osteoporosis, especially in postmenopausal 
older women. However, further studies are needed in this 
regard. The plants possess the androgen-like properties that 
are important for the promotion of bone health. On the 
other hand, modern pharmaceuticals are also employed to 
quickly promote none mineral density for people at high 
risk. In addition, herbal treatments are supportive and 
slow-acting, and therefore they are suggested to be used 
for prevention and maintenance purposes rather than fast-
acting treatments. 
Ethical considerations
Nile
Conflict of Interests 
The authors have no conflict of interests.
References
1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, 
Tosteson A. Incidence and economic burden of osteoporosis-
related fractures in the United States, 2005-2025. J Bone Miner 
Res. 2007;22(3):465-75. doi: 10.1359/jbmr.061113.
2. Jolly JJ, Chin KY, Alias E, Chua KH, Soelaiman IN. Protective 
effects of selected botanical agents on bone. Int J Environ Res 
Public Health. 2018;15(5). doi: 10.3390/ijerph15050963.
3. Lötters FJ, van den Bergh JP, de Vries F, Rutten-van Mölken MP. 
Current and future incidence and costs of osteoporosis-related 
fractures in the Netherlands: combining claims data with 
BMD measurements. Calcif Tissue Int. 2016;98(3):235-43. doi: 
10.1007/s00223-015-0089-z.
4. Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, 
screening, and treatment: a review. J Womens Health (Larchmt). 
2014;23(7):563-72. doi: 10.1089/jwh.2013.4611.
5. Kwon HY, Ha YC, Yoo JI. Health-related quality of life in 
accordance with fracture history and comorbidities in Korean 
patients with osteoporosis. J Bone Metab. 2016;23(4):199-206. 
doi: 10.11005/jbm.2016.23.4.199.
6. Lems WF, Raterman HG. Critical issues and current challenges 
in osteoporosis and fracture prevention. An overview of unmet 
needs. Ther Adv Musculoskelet Dis. 2017;9(12):299-316. doi: 
10.1177/1759720x17732562.
7. Vondracek SF, Minne P, McDermott MT. Clinical challenges 
in the management of osteoporosis. Clin Interv Aging. 
2008;3(2):315-29.
8. Ekor M. The growing use of herbal medicines: issues relating 
to adverse reactions and challenges in monitoring safety. Front 
Pharmacol. 2014;4:177. doi: 10.3389/fphar.2013.00177.
9. Leung PC, Siu WS. Herbal treatment for osteoporosis: a 
current review. J Tradit Complement Med. 2013;3(2):82-7. doi: 
10.4103/2225-4110.110407.
10. Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, et al. Chinese 
herbal medicine for osteoporosis: a systematic review of 
randomized controlled trails. Evid Based Complement Alternat 
Med. 2013;2013:356260. doi: 10.1155/2013/356260.
11. Gunn CA, Weber JL, Kruger MC. Midlife women, bone health, 
vegetables, herbs and fruit study. The Scarborough Fair study 
protocol. BMC Public Health. 2013;13:23. doi: 10.1186/1471-
2458-13-23.
12. Gunn CA, Weber JL, McGill AT, Kruger MC. Increased intake of 
selected vegetables, herbs and fruit may reduce bone turnover 
in post-menopausal women. Nutrients. 2015;7(4):2499-517. 
doi: 10.3390/nu7042499.
13. Hwang YC, Jeong IK, Ahn KJ, Chung HY. The effects of 
Acanthopanax senticosus extract on bone turnover and bone 
mineral density in Korean postmenopausal women. J Bone 
Miner Metab. 2009;27(5):584-90. doi: 10.1007/s00774-009-
0093-3.
Figure 2. The most important mechanisms of medicinal plants and their 
derivatives.
                                                              Journal of Shahrekord University of Medical Sciences, Volume 21, Issue 5, 2019 235
Effects of medicinal herbs on osteoporosis 
14. Thorup AC, Lambert MN, Kahr HS, Bjerre M, Jeppesen PB. 
Intake of Novel Red Clover Supplementation for 12 Weeks 
Improves Bone Status in Healthy Menopausal Women. Evid 
Based Complement Alternat Med. 2015;2015:689138. doi: 
10.1155/2015/689138.
15. Zhao G, Cai D, Dong S, Fan Y. Clinical observation on 
treatment with the kidney-tonifying prescription in 25 
cases of postmenopausal osteoporosis. J Tradit Chin Med. 
2003;23(2):103-5.
16. Qiu R, Shen R, Zhang P. Treatment of postmenopausal 
osteoporosis with yang huo san zi tang--a report of 30 cases. J 
Tradit Chin Med. 2004;24(2):102-4.
17. Zhang RH, Chen KJ, Lu DX, Zhu XF, Ma XC. A clinical study of 
Yigu capsule in treating postmenopausal osteoporosis. Chin J 
Integr Med. 2005;11(2):97-103.
18. Leung PC, Cheng KF, Chan YH. An innovative herbal product 
for the prevention of osteoporosis. Chin J Integr Med. 
2011;17(10):744-9. doi: 10.1007/s11655-011-0876-y.
19. Yang F, Tang DZ, Cui XJ, Holz JD, Bian Q, Shi Q, et al. Classic 
yin and yang tonic formula for osteopenia: study protocol 
for a randomized controlled trial. Trials. 2011;12:187. doi: 
10.1186/1745-6215-12-187.
20. Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, 
et al. The first multicenter and randomized clinical trial of 
herbal Fufang for treatment of postmenopausal osteoporosis. 
Osteoporos Int. 2012;23(4):1317-27. doi: 10.1007/s00198-
011-1577-2.
21. Yang YP, Shuai B, Shen L, Xu XJ, Ma C, Lv L. Effect of Qing’e 
formula on circulating sclerostin levels in patients with 
postmenopausal osteoporosis. J Huazhong Univ Sci Technolog 
Med Sci. 2015;35(4):525-30. doi: 10.1007/s11596-015-1464-
8.
22. Shi ZY, Zhang XG, Li CW, Liu K, Liang BC, Shi XL. Effect of 
traditional Chinese medicine product, QiangGuYin, on bone 
mineral density and bone turnover in Chinese postmenopausal 
osteoporosis. Evid Based Complement Alternat Med. 
2017;2017:6062707. doi: 10.1155/2017/6062707. 
23. Alshafei MM, Kassem SS, Ramadan MM, Hanafi EM, Saber 
MM, Saber LM, et al. Innovative Food Supplement of Functional 
Seeds Mixture Improved Bone Mineral Density in Menopausal 
Egyptian Women. Int J Pharmacol. 2017;13(8):1055-62. doi: 
10.3923/ijp.2017.1055.1062.
24. Guo N, Li B, Jiang X. The efficacy of a phytoestrogen-rich chinese 
medicine on senile osteoporosis. Farmacia. 2018;66(6):1076-
80. doi: 10.31925/FARMACIA.2018.6.23.
25. Li ZR, Cheng LM, Wang KZ, Yang NP, Yang SH, He W, et al. 
Herbal Fufang Xian Ling Gu Bao prevents corticosteroid-
induced osteonecrosis of the femoral head-A first multicentre, 
randomised, double-blind, placebo-controlled clinical 
trial. J Orthop Translat. 2018;12:36-44. doi: 10.1016/j.
jot.2017.11.001.
26. Lin J, Zhu J, Tian FB, Chen L, Zhang Y, Wang Y, et al. Effects of Ziyin 
Jianghuo Ningxin decoction plus dehydroepiandrosterone and 
femoston in treatment of patients with menopausal symptoms. 
J Tradit Chin Med. 2018;38(5):787-96. doi: 10.1016/S0254-
6272(18)30920-8.
27. Wattanathorn J, Somboonporn W, Sungkamanee S, 
Thukummee W, Muchimapura S. A double-blind placebo-
controlled randomized trial evaluating the effect of 
polyphenol-rich herbal congee on bone turnover markers of 
the perimenopausal and menopausal women. Oxid Med Cell 
Longev. 2018;2018:2091872. doi: 10.1155/2018/2091872.
28. Yun GW, Kang JH, Lee H. Effects of Korean herbal medicine 
(Cheong-A-Won) for treatment of bone mineral density in 
women with osteoporosis: a randomized, double blind, 
placebo controlled trial. Eur J Integr Med. 2018;20:84-9. doi: 
10.1016/j.eujim.2018.04.009.
29. Zheng Y, Wang X, Zhang ZK, Guo B, Dang L, He B, et al. 
Bushen Yijing Fang reduces fall risk in late postmenopausal 
women with osteopenia: a randomized double-blind and 
placebo-controlled trial. Sci Rep. 2019;9(1):2089. doi: 
10.1038/s41598-018-38335-3.
30. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. 
Dietary inclusion of whole soy foods results in significant 
reductions in clinical risk factors for osteoporosis and 
cardiovascular disease in normal postmenopausal women. 
Menopause. 2001;8(5):384-92. doi: 10.1097/00042192-
200109000-00015.
31. Chiechi LM, Secreto G, D’Amore M, Fanelli M, Venturelli 
E, Cantatore F, et al. Efficacy of a soy rich diet in preventing 
postmenopausal osteoporosis: the Menfis randomized 
trial. Maturitas. 2002;42(4):295-300. doi: 10.1016/s0378-
5122(02)00158-5.
32. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Beneficial effect of soy 
isoflavones on bone mineral content was modified by years since 
menopause, body weight, and calcium intake: a double-blind, 
randomized, controlled trial. Menopause. 2004;11(3):246-54. 
doi: 10.1097/01.gme.0000094394.59028.46.
33. Ye YB, Tang XY, Verbruggen MA, Su YX. Soy isoflavones 
attenuate bone loss in early postmenopausal Chinese women: 
a single-blind randomized, placebo-controlled trial. Eur J Nutr. 
2006;45(6):327-34. doi: 10.1007/s00394-006-0602-2.
34. Wu J, Oka J, Ezaki J, Ohtomo T, Ueno T, Uchiyama S, et al. 
Possible role of equol status in the effects of isoflavone on 
bone and fat mass in postmenopausal Japanese women: a 
double-blind, randomized, controlled trial. Menopause. 
2007;14(5):866-74. doi: 10.1097/gme.0b013e3180305299.
35. Shedd-Wise KM, Alekel DL, Hofmann H, Hanson KB, Schiferl 
DJ, Hanson LN, et al. The soy isoflavones for reducing bone 
loss study: 3-yr effects on pQCT bone mineral density and 
strength measures in postmenopausal women. J Clin Densitom. 
2011;14(1):47-57. doi: 10.1016/j.jocd.2010.11.003.
36. Lee H, Choue R, Lim H. Effect of soy isoflavones supplement 
on climacteric symptoms, bone biomarkers, and quality of 
life in Korean postmenopausal women: a randomized clinical 
trial. Nutr Res Pract. 2017;11(3):223-31. doi: 10.4162/
nrp.2017.11.3.223.
37. Tit DM, Bungau S, Iovan C, Nistor Cseppento DC, Endres L, 
Sava C, et al. Effects of the hormone replacement therapy and 
of soy isoflavones on bone resorption in postmenopause. J Clin 
Med. 2018;7(10). doi: 10.3390/jcm7100297.
38. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Thatcher NJ, 
Kilpatrick ES, et al. Soy reduces bone turnover markers in 
women during early menopause: a randomized controlled 
trial. J Bone Miner Res. 2017;32(1):157-64. doi: 10.1002/
jbmr.2927.
39. Levis S, Strickman-Stein N, Doerge DR, Krischer J. Design 
and baseline characteristics of the soy phytoestrogens as 
replacement estrogen (SPARE) study--a clinical trial of the 
effects of soy isoflavones in menopausal women. Contemp Clin 
Trials. 2010;31(4):293-302. doi: 10.1016/j.cct.2010.03.007.
40. Roudsari AH, Tahbaz F, Hossein-Nezhad A, Arjmandi B, 
Larijani B, Kimiagar SM. Assessment of soy phytoestrogens’ 
effects on bone turnover indicators in menopausal women 
with osteopenia in Iran: a before and after clinical trial. Nutr J. 
2005;4:30. doi: 10.1186/1475-2891-4-30.
41. Kok L, Kreijkamp-Kaspers S, Grobbee DE, van der Schouw 
YT. Design and baseline characteristics of a trial on health 
effects of soy protein with isoflavones in postmenopausal 
women. Maturitas. 2004;47(1):21-9. doi: 10.1016/s0378-
 Journal of Shahrekord University of Medical Sciences, Volume 21, Issue 5, 2019                                                             236
Habibi Ghahfarrokhi et al 
5122(03)00243-3.
42. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, 
et al. Effects of the phytoestrogen genistein on bone metabolism 
in osteopenic postmenopausal women: a randomized trial. 
Ann Intern Med. 2007;146(12):839-47. doi: 10.7326/0003-
4819-146-12-200706190-00005.
43. Atteritano M, Pernice F, Mazzaferro S, Mantuano S, Frisina 
A, D’Anna R, et al. Effects of phytoestrogen genistein on 
cytogenetic biomarkers in postmenopausal women: 1 year 
randomized, placebo-controlled study. Eur J Pharmacol. 
2008;589(1-3):22-6. doi: 10.1016/j.ejphar.2008.04.049.
44. Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano 
V, et al. Breast safety and efficacy of genistein aglycone for 
postmenopausal bone loss: a follow-up study. J Clin Endocrinol 
Metab. 2008;93(12):4787-96. doi: 10.1210/jc.2008-1087.
45. Atteritano M, Mazzaferro S, Frisina A, Cannata ML, Bitto A, 
D’Anna R, et al. Genistein effects on quantitative ultrasound 
parameters and bone mineral density in osteopenic 
postmenopausal women. Osteoporos Int. 2009;20(11):1947-
54. doi: 10.1007/s00198-009-0883-4.
46. Weaver CM, Martin BR, Jackson GS, McCabe GP, Nolan JR, 
McCabe LD, et al. Antiresorptive effects of phytoestrogen 
supplements compared with estradiol or risedronate in 
postmenopausal women using (41) Ca methodology. J Clin 
Endocrinol Metab. 2009;94(10):3798-805. doi: 10.1210/
jc.2009-0332.
47. Lappe J, Kunz I, Bendik I, Prudence K, Weber P, Recker R, et 
al. Effect of a combination of genistein, polyunsaturated fatty 
acids and vitamins D3 and K1 on bone mineral density in 
postmenopausal women: a randomized, placebo-controlled, 
double-blind pilot study. Eur J Nutr. 2013;52(1):203-15. doi: 
10.1007/s00394-012-0304-x.
48. Pawlowski JW, Martin BR, McCabe GP, McCabe L, Jackson 
GS, Peacock M, et al. Impact of equol-producing capacity 
and soy-isoflavone profiles of supplements on bone calcium 
retention in postmenopausal women: a randomized crossover 
trial. Am J Clin Nutr. 2015;102(3):695-703. doi: 10.3945/
ajcn.114.093906.
49. Arcoraci V, Atteritano M, Squadrito F, D’Anna R, Marini 
H, Santoro D, et al. Antiosteoporotic Activity of Genistein 
Aglycone in Postmenopausal Women: Evidence from a Post-
Hoc Analysis of a Multicenter Randomized Controlled Trial. 
Nutrients. 2017;9(2). doi: 10.3390/nu9020179.
50. Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. 
Tofupill/Femarelle (DT56a): a new phyto-selective estrogen 
receptor modulator-like substance for the treatment of 
postmenopausal bone loss. Menopause. 2003;10(6):522-5. 
doi: 10.1097/01.gme.0000064864.58809.77.
51. Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen 
flavonoids exert beneficial effect on preventing bone loss 
in late postmenopausal women: a 24-month randomized, 
double-blind and placebo-controlled trial. J Bone Miner Res. 
2007;22(7):1072-9. doi: 10.1359/jbmr.070405.
52. Lamb JJ, Holick MF, Lerman RH, Konda VR, Minich DM, Desai 
A, et al. Nutritional supplementation of hop rho iso-alpha acids, 
berberine, vitamin D(3), and vitamin K(1) produces a favorable 
bone biomarker profile supporting healthy bone metabolism in 
postmenopausal women with metabolic syndrome. Nutr Res. 
2011;31(5):347-55. doi: 10.1016/j.nutres.2011.03.016.
53. Granado-Lorencio F, Lagarda MJ, Garcia-López FJ, Sánchez-
Siles LM, Blanco-Navarro I, Alegría A, et al. Effect of beta-
cryptoxanthin plus phytosterols on cardiovascular risk and bone 
turnover markers in post-menopausal women: a randomized 
crossover trial. Nutr Metab Cardiovasc Dis. 2014;24(10):1090-
6. doi: 10.1016/j.numecd.2014.04.013.
54. Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F. 
Long-term consumption of isoflavone-enriched foods does not 
affect bone mineral density, bone metabolism, or hormonal 
status in early postmenopausal women: a randomized, 
double-blind, placebo controlled study. Am J Clin Nutr. 
2008;87(3):761-70. doi: 10.1093/ajcn/87.3.761.
55. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, 
Krischer J. Soy isoflavones in the prevention of menopausal 
bone loss and menopausal symptoms: a randomized, double-
blind trial. Arch Intern Med. 2011;171(15):1363-9. doi: 
10.1001/archinternmed.2011.330.
56. Tai TY, Tsai KS, Tu ST, Wu JS, Chang CI, Chen CL, et al. The effect 
of soy isoflavone on bone mineral density in postmenopausal 
Taiwanese women with bone loss: a 2-year randomized 
double-blind placebo-controlled study. Osteoporos Int. 
2012;23(5):1571-80. doi: 10.1007/s00198-011-1750-7.
57. Lambert MNT, Thybo CB, Lykkeboe S, Rasmussen LM, Frette X, 
Christensen LP, et al. Combined bioavailable isoflavones and 
probiotics improve bone status and estrogen metabolism in 
postmenopausal osteopenic women: a randomized controlled 
trial. Am J Clin Nutr. 2017;106(3):909-20. doi: 10.3945/
ajcn.117.153353.
58. Hasani-Ranjbar S, Jouyandeh Z, Qorbani M, Hemmatabadi M, 
Larijani B. The effect of semelil (angipars(R)) on bone resorption 
and bone formation markers in type 2 diabetic patients. Daru. 
2012;20(1):84. doi: 10.1186/2008-2231-20-84.
59. Alekel DL, Van Loan MD, Koehler KJ, Hanson LN, Stewart 
JW, Hanson KB, et al. The soy isoflavones for reducing bone 
loss (SIRBL) study: a 3-y randomized controlled trial in 
postmenopausal women. Am J Clin Nutr. 2010;91(1):218-30. 
doi: 10.3945/ajcn.2009.28306.
60. Leali PT, Muresu F, Melis A, Ruggiu A, Zachos A, Doria C. 
Skeletal fragility definition. Clin Cases Miner Bone Metab. 
2011;8(2):11-3.
61. Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. 
Chronic Dis Transl Med. 2015;1(1):9-13. doi: 10.1016/j.
cdtm.2015.02.006.
62. Tella SH, Gallagher JC. Prevention and treatment of 
postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 
2014;142:155-70. doi: 10.1016/j.jsbmb.2013.09.008.
63. Bartl R, Frisch B. Osteoporosis: diagnosis, prevention, therapy. 
Berlin: Springer Science & Business Media; 2009.
64. Nadia ME, Nazrun AS, Norazlina M, Isa NM, Norliza M, 
Ima Nirwana S. The anti-inflammatory, phytoestrogenic, 
and antioxidative role of Labisia pumila in prevention 
of postmenopausal osteoporosis. Adv Pharmacol Sci. 
2012;2012:706905. doi: 10.1155/2012/706905.
65. Jia M, Nie Y, Cao DP, Xue YY, Wang JS, Zhao L, et al. Potential 
antiosteoporotic agents from plants: a comprehensive review. 
Evid Based Complement Alternat Med. 2012;2012:364604. 
doi: 10.1155/2012/364604.
66. Sungkamanee S, Wattanathorn J, Muchimapura S, Thukham-
mee W. Antiosteoporotic effect of combined extract of Morus 
alba and Polygonum odoratum. Oxid Med Cell Longev. 
2014;2014:579305. doi: 10.1155/2014/579305.
67. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, 
Huber JC. Side effects of phytoestrogens: a meta-analysis of 
randomized trials. Am J Med. 2009;122(10):939-46.e9. doi: 
10.1016/j.amjmed.2009.04.018.
